Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Najvýznamnejšie klinické správy z konferencie ASCO 2017 v problematike nádorov gastrointestinálneho traktu
29 septembra, 2020 8:29 pmPočas prvého júnového týždňa tohto roka sa konal v Chicagu tradičný výročný kongres Americkej onkologickej spoločnosti (ASCO). Ako obvykle v rámci prednášok...
Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer – Metastatic Abstract number: 1005 Authors: Guy Heinrich Maria...
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo-controlled D-CARE study
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 501 Authors: Robert E. Coleman, Dianne Finkelstein,...
De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 507 Authors: Valentina Guarneri, Maria Vittoria Dieci,...
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 506 Authors: Helena Margaret Earl, Louise Hiller,...
Persephone Demonstrates Noninferiority of Shorter Duration Adjuvant Trastuzumab in HER2-Positive Breast Cancer
23 septembra, 2020 4:53 pmJune 5, 2018 A 6-month duration of adjuvant trastuzumab with chemotherapy was found to be noninferior to 12 months...
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: LBA1 Authors: Joseph A. Sparano, Robert James...
TAILORx: Many Women With Early Breast Cancer Can Avoid Chemotherapy
23 septembra, 2020 4:53 pmJune 4, 2018 Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive,...
KARCINOM PRSU NA ASCO 2018
23 septembra, 2020 4:53 pmNejvětší novinky prezentované na posledních konferencích ASCO se zpravidla netýkaly karcinomu prsu, ale jiných solidních nádorů, jako je maligní melanom, karcinom...
Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma: A 3-arm randomized control study
23 septembra, 2020 4:53 pmMeeting: 2018 ASCO Annual Meeting Track: Gynecologic Cancer Abstract number: 5529 Authors: He Huang, Li Yang, Yue...